Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Targeted drug trial aims to starve advanced cancers by blocking their DNA repair

NCT ID NCT04550494

Summary

This study is testing whether the drug talazoparib can help control advanced cancers in patients whose tumors have specific genetic mutations that affect how cells repair damaged DNA. The trial will enroll about 36 adults with various advanced solid tumors (like breast, ovarian, prostate, pancreatic, or gastric cancer) who have these mutations and whose disease has progressed after standard treatments. Researchers aim to see if the drug works by blocking a key DNA repair protein in cancer cells, potentially causing them to die, and to learn if patients can benefit from trying different drugs in this class one after another.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • National Cancer Institute Developmental Therapeutics Clinic

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact

    Contact Phone: •••-•••-••••

  • National Institutes of Health Clinical Center

    ACTIVE_NOT_RECRUITING

    Bethesda, Maryland, 20892, United States

  • UF Health Cancer Institute - Gainesville

    RECRUITING

    Gainesville, Florida, 32610, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.